Tixel i®: Advancing Management of Evaporative Dry Eye with Thermo- Mechanical Action®

Evaporative Dry Eye Disease (DED), primarily driven by Meibomian Gland Dysfunction (MGD), affects over 30 million individuals in the United States.Tixel i , a recently FDA-cleared, non-invasive device, applies localized heat and pressure to the external eyelid surface using Thermo-Mechanical Action (TMA ).This commentary reviews findings pivotal studies, regulatory submissions, and real-world clinical experience demonstrating Tixel i's safety, tolerability, and sustained improvements in TBUT, MGS, and OSDI.Real-world results in both routine and treatment-resistant patients further support its versatility.With a short treatment duration, minimal discomfort, and durable clinical outcomes, Tixel i offers an efficient, first-line option for managing DED associated with MGD.